LOS ANGELES - Moderna announced on Thursday that data from an ongoing trial of its COVID-19 vaccine for teens ages 12-17 was 96% effective against the novel coronavirus.
No additional side effects or serious safety concerns were reported so far, according to the company. The trial consists of 3,235 teenagers, and efficacy for the vaccine was approximately 96% for the participants who received at least one injection, Moderna reported.
The company also said that because incidence rate of COVID-19 is lower in adolescents and teenagers, the vaccine’s effectiveness on the trial patients is mainly against milder symptoms of the disease. RELATED: COVID-19 vaccine boosters likely needed every 9 to 12 months, Moderna president saysThe company said.